Non-Hallucinogenic Psychedelics: The Science of Separating the Therapy from the Trip
Science | May 24, 2026
A new generation of non-hallucinogenic psychedelics is emerging as a potential depression treatment that could be prescribed in a standard clinical setting, without the supervised eight-hour sessions that make current psychedelic therapy inaccessible at scale. UC Davis researchers published findings in May 2026 describing compounds that activate the same serotonin receptors linked to the neuroplasticity and antidepressant effects of classic psychedelics, without producing hallucination-like behavior in animal models.
This piece explains what we know about how these compounds work, what the clinical evidence shows so far, and what the field does not yet understand.
What Psychedelics Actually Do in the Brain
To understand why non-hallucinogenic psychedelic research matters, it helps to start with what classic psychedelics, psilocybin, LSD, and DMT among them, actually do in the brain.
These compounds bind primarily to the 5-HT2A serotonin receptor, a protein found on the surface of neurons in the prefrontal cortex and other regions involved in mood, cognition, and self-referential thinking. Activation of 5-HT2A sets off a cascade: dendrites sprout, synaptic connections multiply, and the brain temporarily becomes more flexible in how it processes information. Neuroscientists call this property neuroplasticity, and its absence or reduction is a defining feature of treatment-resistant depression and post-traumatic stress disorder.
The hallucinations, time distortion, and ego dissolution that characterize a psychedelic experience are also products of 5-HT2A activation, but they appear to arise through a distinct intracellular pathway. Research at Johns Hopkins, Imperial College London, and the UC Davis Institute for Psychedelics and Neurotherapeutics has found that the receptor can be activated in ways that promote plasticity without fully engaging the pathway responsible for perceptual effects.
This distinction is the scientific foundation of the non-hallucinogenic psychedelics field. The question researchers are trying to answer is whether the two effects can be cleanly separated in a drug candidate, and if so, whether the resulting compound still works therapeutically.
How the UC Davis Team Built Compounds from Scratch
Most psychedelic-inspired drug development begins by taking an existing molecule, psilocybin for instance, and modifying its molecular edges to alter its pharmacology. Researchers tweak functional groups, change the positions of atoms, or add chemical flags that block specific receptor interactions. The resulting compounds are chemically related to their psychedelic parents, which means they can inherit unwanted properties from those parents as well as useful ones.
The UC Davis team took a different approach. Starting with amino acids, the building blocks of proteins, the researchers used ultraviolet light to generate entirely novel chemical structures with no precedent in existing psychedelic pharmacology. The resulting compounds were described in the Journal of the American Chemical Society.
In cell cultures, the compounds activated 5-HT2A receptors. In animal models, they produced markers associated with neuroplasticity, the synaptic and dendritic changes that researchers believe underlie the antidepressant and anti-anxiety effects of psychedelics. In behavioral tests designed to detect hallucination-like responses in mice, including the head-twitch response that is a standard proxy for classic psychedelic effects, the compounds showed no significant activity.
“Starting from amino acids gave us chemical space that existing psychedelic scaffolds do not occupy,” the study’s lead authors noted in the paper, explaining that genuinely novel structures reduce the risk of importing the pharmacological baggage of the parent compounds.
The practical implication, if the findings translate to humans, would be a class of drugs that a psychiatrist could prescribe in a conventional clinical setting without the need for a supervised eight-hour session, a specially trained therapist on site, or the regulatory overhead that currently makes psychedelic therapy expensive and difficult to access at scale.
The Broader Scientific Context
The UC Davis work does not stand alone. Several research groups and companies have been pursuing the non-hallucinogenic angle from different directions.
Delix Therapeutics, a San Francisco startup founded by UC Davis neuroscientist David Olson, is developing what it calls “tabernanthalog” and related compounds, non-hallucinogenic analogs of ibogaine, a psychedelic with demonstrated efficacy against addiction but a dangerous cardiac profile. Delix’s lead compound, DLX-001, is currently in clinical development for major depressive disorder.
Beckley Psytech, a UK-based company, is taking a different route, developing formulations of existing psychedelics, including 5-MeO-DMT, that use dosing and delivery methods to reduce the duration and intensity of the perceptual experience while preserving the therapeutic window. Its compound BPL-003 is in Phase II trials in the UK.
ATAI Life Sciences, one of the better-capitalized players in the psychedelic therapeutics space, has a portfolio that spans both classic psychedelic-assisted therapies and reduced-hallucination analogs.
The common thread across these approaches is the hypothesis that the neuroplastic mechanism of psychedelics, the structural changes to neurons and synapses, can be separated from the subjective experience. The UC Davis paper provides the strongest evidence yet that this can be done at the molecular level. Whether it holds up in human pharmacology is the next question.
The Unresolved Debate: Is the Trip Part of the Treatment?
The field’s central scientific disagreement is whether the psychedelic experience itself is therapeutic, rather than merely a consequence of the same mechanism that drives neuroplasticity.
Researchers including Robin Carhart-Harris, now at the University of California San Francisco, have argued that the psychological content of a psychedelic session, the confrontation with suppressed memories, the dissolution of habitual thought patterns, the moments of what subjects often describe as insight or acceptance, is not a side effect but a mechanism. On this view, a compound that promotes neuroplasticity without producing any perceptual experience might generate inferior clinical outcomes, because it omits the psychological processing that makes the neuroplastic window therapeutically useful.
The counterargument draws on the ketamine evidence. Ketamine, which produces dissociative effects rather than classic psychedelic ones, relieves treatment-resistant depression in hours and has been used clinically in this context for years. Esketamine, an S-enantiomer ketamine formulation sold as Spravato, is FDA-approved for treatment-resistant depression and major depressive disorder with suicidal ideation. Some patients respond to sub-anesthetic ketamine doses that produce minimal perceptual effects. This suggests that neuroplasticity and receptor-level changes, rather than the subjective experience per se, may do significant clinical work.
The honest current state of the evidence is that the field cannot cleanly disentangle these factors. Psychedelic clinical trials are difficult to blind, because participants generally know whether they are in the active or placebo arm, which introduces expectation effects that can inflate apparent response rates. Designing a trial that separates the neuroplastic mechanism from the psychological experience requires having both a hallucinogenic and a non-hallucinogenic version of the same compound available for head-to-head comparison, which is exactly what the UC Davis approach makes possible for the first time.
Non-Hallucinogenic Psychedelics as a Depression Treatment: The Commercial Case
The business case for non-hallucinogenic psychedelic therapeutics is large. Classic psychedelic therapy, as currently practiced in clinical settings, requires a patient to take a scheduled controlled substance in a supervised clinic for six to eight hours. Sessions cost between $1,000 and $3,000, are rarely covered by insurance, and are available only in jurisdictions that have created specific legal frameworks for the therapy, including Oregon, Colorado, and Australia.
A pill that could be prescribed by a primary care physician and taken at home, generating the neuroplastic benefit without the perceptual experience, would be compatible with the existing psychiatric system. The addressable patient population spans treatment-resistant depression, PTSD, OCD, and addiction disorders, numbering in the tens of millions in the United States alone.
The regulatory pathway for such a drug would be standard FDA drug approval rather than the novel framework that psychedelic-assisted therapy requires. That is a significant advantage in terms of speed, cost, and the breadth of prescribers who could offer it.
What Remains Unknown
Several fundamental questions are unresolved.
The durability of the neuroplastic effect in humans is not well characterized. Animal models consistently show synapse formation and dendrite growth, but how long these structural changes persist in people, and whether they translate into sustained clinical benefit, remains unclear. The field needs long-term follow-up data from controlled human trials, and those trials are in early stages.
The safety profile of chronic use is genuinely unknown for the novel compounds being developed. Classic psychedelics have a low acute toxicity profile in humans. The amino acid-derived compounds produced by the UC Davis team have no history of human exposure. Long-term effects on the serotonin system and other receptor targets will require dedicated safety studies before any compound could be approved.
The question of patient selection is also open. Depression is a heterogeneous condition with multiple biological subtypes. Patients who respond to ketamine are not always the same patients who respond to SSRIs or MAOIs. It is possible that neuroplasticity-promoting psychedelic analogs will work well for a specific subgroup, rather than as a broad replacement for existing antidepressants.
Finally, and most fundamentally, the head-to-head trial comparing hallucinogenic and non-hallucinogenic compounds has not been done. Until that trial exists, the debate between Carhart-Harris and Olson cannot be resolved with data rather than argument.
Where the Field Is Headed
The UC Davis study represents a methodological step forward as much as a pharmacological one. Beginning from amino acids rather than modifying existing psychedelics opens a larger and largely unexplored area of chemical space. The ability to use UV light to generate molecular variants means the approach scales: researchers can produce and screen large numbers of candidates without starting from scratch each time.
The broader arc of the field is toward precision. Rather than administering a single psychedelic compound to every patient with a depression diagnosis, researchers are working toward matching specific molecular tools to specific neurobiological profiles. That requires understanding not just which receptors a compound activates, but which intracellular pathways it engages, in which brain regions, and in which genetic and experiential contexts.
The clinical application of that level of precision is years away. But the UC Davis findings represent a concrete addition to the evidence that the therapeutic benefits of psychedelics can be separated, at least partially, from their perceptual effects. For the millions of patients for whom existing antidepressants have not worked, that is a consequential line of research, and one that deserves more attention than it typically receives outside specialist circles.
Sources: New Psychedelic-Like Drugs Could Treat Depression Without Making You Trip, ScienceDaily | Psychedelics and Non-Hallucinogenic Analogs Work Through the Same Receptor, UC Davis | UC Davis Establishes Institute for Psychedelics and Neurotherapeutics, UC Davis | Psychedelics Without the Hallucinations: A New Mental Health Treatment, University of Chicago News | LSD Analogue for Treating Psychiatric Diseases, NIH
